2017 ECIL 7 vaccine guidelines

Cordonnier, Catherine; Mikulska, Małgorzata; Einarsdottir, Sigrun; Cesaro, Simone; Ljungman, Per

doi:10.1016/s1473-3099(19)30277-4

Cited by 10 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has also been observed for other vaccinations (e.g., influenza). [15][16] Our results suggest that the low serologic response rate to anti-SARS-CoV-2 vaccines in patients with HM may translate to higher rates of infections. This has previously been described following monoclonal antibody treatment.…”

mentioning

confidence: 83%

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Pagano

Salmanton‐García

Marchesi

et al. 2022

Blood

View full text Add to dashboard Cite

In a Plenary Paper, Mittelman and colleagues assess the relative clinical efficacy of mRNA vaccination on COVID-19 disease incidence and outcomes in patients with hematologic malignancies compared with healthy matched controls. This population-based study from Israel links prior observations of poor serologic responses to vaccination to higher risk for breakthrough infection, hospitalization, and death in patients with blood cancer, especially those on active antineoplastic therapy. In an accompanying Letter to Blood, Pagano et al provide supportive data using a multination survey approach to capture outcomes for COVID-19 in vaccinated patients with hematologic neoplasms. They also emphasize the higher risk among patients with lymphoid malignancies. Together, these findings argue for both continued deployment of booster programs and ongoing public health guidance for this vulnerable group.

show abstract

mentioning

confidence: 83%

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Pagano

Salmanton‐García

Marchesi

et al. 2022

Blood

View full text Add to dashboard Cite

show abstract

“…Data indicates the added rationale for active immunization of CAR-T recipients by the administration of vaccinations. We should clearly keep in mind that there are contraindications for vaccinations with killed or inactivated vaccine in patients with concurrent immunosuppressive or cytotoxic therapy; and contraindications for live and non-live adjuvant vaccines in the period <2 years post allogeneic HCT, and up to eight months after the last dose of immunoglobulin replacement therapy [27][28][29][30]. The EBMT/European Haematology Association (EHA) cooperative group of experts announced recommendations pertaining to the management of patients undergoing therapy with CAR-T [12].…”

Section: Discussionmentioning

confidence: 99%

Vaccinations following CAR-T cell therapy: summary of reported cases and state-of-the-art review of current recommendations

Styczyński

Sadlok

et al. 2022

Acta Haematol Pol.

View full text Add to dashboard Cite

Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is a modern breakthrough technology used in the treatment of B-lineage lymphoid malignancies. These malignancies include acute lymphoblastic leukemia, non-Hodgkin lymphoma, and plasma cell disorders. CAR-T therapy combines cellular therapy, gene therapy, and individualized therapy. The objective of this paper was to review the latest clinical knowledge, and summarize the reported data pertaining to vaccinations in patients after CAR-T therapy. Material and methods: We carried out a review of published original studies as indexed in PubMed, and a review of abstracts presented during major hematology meetings. Results: Overall, 22 original studies were reviewed and considered suitable for analysis regarding the efficacy of vaccinations for patients who had received CAR-T therapy. Data was divided into three groupings: the efficacy of vaccination against coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); the efficacy of vaccination against influenza; and the efficacy of post-CAR-T immunization persistence of vaccination performed before CAR-T therapy. Humoral and cellular response to SARS-CoV-2 vaccination was positive for 36.5% and 72.2% of patients, respectively. The positive response to the influenza vaccine was 40% when administered prior to CAR-T therapy, as opposed to 31% after. Seroprotection for vaccine-preventable infections within 3-6 months after CAR-T was comparable to that of the general population, although it was determined to be less effective against specific pathogens (S. pneumoniae, B. pertussis, H. influenzae) in most patients. Conclusions: In cases of incomplete immune reconstitution, there is a high likelihood of a limited response to vaccination. Regarding the SARS-CoV-2/COVID-19 vaccine, T-cell-induced protection is relatively significant. Therefore, B-cell aplasia is not a contraindication for vaccination in CAR-T patients. The consensus of European Society of Blood and Marrow Transplantation/European Hematology Association experts is that vaccination after CAR-T therapy is beneficial in order to reduce the rates of infection, and eventually to improve clinical course.

show abstract

“…Allo‐HSCT recipients are thus confirmed to respond to vaccines yet at a lower extent than healthy individuals [11]. In fact, the response depends on a series of factors, especially the fact of being under treatment with chemotherapy/immunosuppressive drugs as well as the severity of immunosuppression at the time of vaccination.…”

Section: Discussionmentioning

confidence: 99%

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients

Chevallier

Coste‐Burel²,

Bourgeois

et al. 2021

eJHaem

View full text Add to dashboard Cite

This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer‐BioNTech) in 112 Allo‐HSCT patients. Antibody response to SARS‐CoV‐2 spike protein receptor‐binding domain was tested at the time of the second injection (Roche Elecsys). The study also included a non‐randomized control arm of 26 healthy controls. This study shows that a first dose of SARS‐CoV‐2 messenger RNA vaccine is safe and provides a 55% rate of seroconversion in allotransplanted patients compared to 100% for the controls ( p < 0.001). Factors influencing the absence of response in patients were recent transplantation (<2 years), lymphopenia (<1 × 10 9 /L) and immunosuppressive treatment or chemotherapy at the time of vaccination.

show abstract

2017 ECIL 7 vaccine guidelines

Cited by 10 publications

References 9 publications

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Vaccinations following CAR-T cell therapy: summary of reported cases and state-of-the-art review of current recommendations

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients

Contact Info

Product

Resources

About